Form 4: Conexeu Sciences Executive Reports Stock Transaction
Insider Transaction (Form 4)
David Robert Bogart, Chief Commercial Officer and a Director of Conexeu Sciences Inc., reported multiple transactions in common stock on September 25, 2026.
Summary
- Option exercise/conversion: acquired 750,000 Common Stock at $0.00 ($750) on September 25, 2026; holds 1,812,500 after (Direct).
- Option exercise/conversion: disposed of 750,000 Performance Warrants on September 25, 2026; holds 250,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
David Robert Bogart — Director, Officer (Chief Commercial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-25 | Option exercise/conversion | Common Stock | 750,000 | $0 | $750 | 1,812,500 |
| 2026-09-25 | Option exercise/conversion | Performance Warrants | 750,000 | — | — | 250,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-25 | Option exercise/conversion (750,000 shares) |
| 2026-09-25 | Option exercise/conversion (750,000 shares) |
Keywords
insider transaction, Form 4, CNXU, Conexeu Sciences Inc., neutral, David Robert Bogart
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.